REG - Aptamer Group PLC - Block Listing Interim Review

AptamerAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250828:nRSb9463Wa&default-theme=true

RNS Number : 9463W  Aptamer Group PLC  28 August 2025

 

28 August 2025

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Block Listing Interim Review

 

Aptamer Group plc (AIM: APTA), the leading developer of next-generation
synthetic binders delivering innovation to the life science industry, makes
the following notification pursuant to AIM Rule 29 and Schedule 6 of the AIM
Rules for Companies regarding its existing block admission:

 

 Name of Company                                                                 Aptamer Group plc
 Name of Scheme                                                                  The Aptamer Group EMI Share Option Scheme
 Period of Return (from/to)                                                      24 February 2025 to 25 August 2025
 Number and class of securities not issued at the start of the period under the  576,053 Ordinary Shares
 scheme
 Number of securities issued under the scheme during the period                  0
 Balance under the scheme of securities not yet issued at the end of the period  576,053 Ordinary Shares
 Number and class of securities originally admitted and the date of admission    2,063,200 Ordinary Shares on 25 February 2022
 Name of contact and telephone number                                            Andrew Rapson +44 (0) 1904 217 404

 

- Ends -

 

For further information, please contact:

 

 Aptamer Group plc                                               +44 (0) 1904 217 404 

 Dr Arron Tolley, Chief Executive Officer
 SPARK Advisory Partners Limited - Nominated Adviser             +44 (0) 20 3368 3550 

 Andrew Emmott
 Turner Pope Investments (TPI) Limited - Broker                  +44 (0) 20 3657 0050 

 James Pope / Andrew Thacker 
 Northstar Communications Limited - Investor Relations           +44 (0) 113 730 3896

 Sarah Hollins

 

About Aptamer Group

 

Aptamer Group is a leading developer of next-generation synthetic binders
delivering innovation to the life sciences industry. The Group develops
Optimer® binders, advanced molecules that work like antibodies by attaching
to specific targets in the body. These binders are used in medicine,
diagnostic tests, and research tools, offering benefits like high stability,
reliable performance, and lower costs compared to traditional antibodies.

 

Aptamer operates a fee-for-service business in the US$210 billion market for
antibody alternatives, working with all top 10 global pharmaceutical
companies. It is also building valuable Optimer® assets with partners, aiming
for future licensing revenue.

 

Founded in 2008, the Group listed on the London Stock Exchange AIM market in
December 2021 and is headquartered in York, UK.

 

To register for news alerts by email go to
https://aptamergroup.com/investors/investor-news-email-alerts/
(https://aptamergroup.com/investors/investor-news-email-alerts/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRDDLFLEVLZBBD